Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Mar 2014

Cairncross J Gregory, Wang Meihua, Jenkins Robert B, Shaw Edward G, Giannini Caterina, Brachman David G, Buckner Jan C, Fink Karen L, Souhami Luis, Laperriere Normand J, Huse Jason T, Mehta Minesh P, Curran Walter J

Abstract excerpt

PURPOSE: Patients with 1p/19q codeleted anaplastic oligodendroglial tumors who participated in RTOG (Radiation Therapy Oncology Group) 9402 lived much longer after chemoradiotherapy (CRT) than radiation therapy (RT) alone. However, some patients with noncodeleted tumors also benefited from CRT; survival curves separated after the median had been reached, and significantly more patients lived ≥ 10 years after CRT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemoradiotherapy
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Oligodendroglioma

Share to Patient Selection

Share to Precision Medicine

Share to Proportional Hazards Models

Share to Vincristine

Source

Open in PubMed Open full text

Identifiers

PMID: 24516018
DOI: 10.1200/JCO.2013.49.3726
PMCID: PMC3940537

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.PMID 24516018Read ↗

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.Semantic proximity Read ↗

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.Semantic proximity Read ↗

Genetic landscape of extreme responders with anaplastic oligodendroglioma.Semantic proximity Read ↗

Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.Semantic proximity Read ↗

Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomasSemantic proximity Read ↗

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy.Semantic proximity Read ↗

Do Long-Term Survivor Primary Glioblastoma Patients Harbor IDH1 Mutations?Semantic proximity Read ↗

Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.Semantic proximity Read ↗

The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas.Semantic proximity Read ↗

IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.Semantic proximity Read ↗

Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomideSemantic proximity Read ↗

Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.